CAPE TOWN, South Africa--20 Jul--PRNewswire-AsiaNet/InfoQuest
Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding efficacy between Viramune(R) (nevirapine) and ritonavir boosted atazanavir (atazanavir/r) both combined with tenofovir and emtricitabine (Truvada(R)). This head-to-head study also showed Viramune(R)'s more favourable effect on the lipid profile and now clearly confirms the combination's place as an important first line therapy for patients with HIV.
To view the Multimedia News Release, please click:
http://www.prnewswire.com/mnr/boehringeringelheim/39137/
"ARTEN puts to rest the concerns over a potential lack of efficacy of Viramune(R) in combination with Truvada(R)," lead investigator of the ARTEN study, Professor Vicente Soriano, Assistant Director of the Department of Infectious Diseases, Hospital Carlos III, Madrid said. "The results confirm that the combination of Viramune(R) and Truvada(R) is a highly efficacious combination that offers significant benefit even more so to patients with cardiovascular risk."
ARTEN is the first large-scale prospective study to compare two frequently prescribed lipid friendly, antiretrovirals(ARVs): atazanavir and Viramune(R).(1,2) Compared to values at baseline, Viramune(R) increased
absolute HDL-c (the so called good cholesterol) to more than two-fold the value achieved with atazanavir/r (9.7 mg/dL vs 3.9 mg/dL (P